Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
14.70
+0.61 (4.33%)
Dec 26, 2024, 4:00 PM EST - Market closed
Tyra Biosciences Employees
Tyra Biosciences had 49 employees as of December 31, 2023. The number of employees increased by 11 or 28.95% compared to the previous year.
Employees
49
Change (1Y)
11
Growth (1Y)
28.95%
Revenue / Employee
n/a
Profits / Employee
-$1,708,980
Market Cap
773.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49 | 11 | 28.95% |
| Dec 31, 2022 | 38 | 13 | 52.00% |
| Dec 31, 2021 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| agilon health | 1,117 |
| Castle Biosciences | 610 |
| Axogen | 428 |
| Cronos Group | 356 |
| Ironwood Pharmaceuticals | 267 |
| Cullinan Therapeutics | 85 |
| Tectonic Therapeutic | 44 |
TYRA News
- 6 weeks ago - Tyra Biosciences to Present at Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PRNewsWire
- 2 months ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PRNewsWire
- 2 months ago - Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
- 2 months ago - Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PRNewsWire
- 2 months ago - Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - PRNewsWire
- 2 months ago - Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point - Seeking Alpha
- 2 months ago - BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Benzinga